Curanex Pharmaceuticals Inc. CURX on Wednesday highlighted five additional patient cases that management believes further ...

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage ...

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most ...

A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

This schematic illustration shows the major organs that are affected by and contribute to the development of pancreatic cancer cachexia. With pancreatic cancer at the center of the crosstalk network, ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...